Fadi Braiteh and Razelle Kurzrock in their article Uncommon tumors and exceptional therapies: paradox or paradigm?, discuss how groundbreaking therapeutic discoveries have been made for uncommon malignancies such as chronic myelogenous leukemia while progress in more extensively studied tumors such as breast cancer has been slow and incremental.
They hypothesise that the pathophysiologic basis for a tumor being rare is one and the same as the reason that it may ultimately be so treatable. The corollary being that new therapies will show their most salutary effects in rare cancers.
Whether this viewpoint is shared by Phylogica - following engagement with key clinical experts - is unknown.
Braiteh and Kurzrock make a compelling case for targeting rare cancers and discuss a new paradigm for the treatment of common cancers.
PYC Price at posting:
1.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)